BAO PHARMA-B (02659) Announces Monthly Return for February 2026

Bulletin Express03-04 16:24

Shanghai Bao Pharmaceuticals Co., Ltd., known as BAO PHARMA-B (02659), has released its monthly return for the period ended 28 February 2026. The authorized share capital comprised 154,327,250 H shares and 171,654,215 domestic shares, both having no change from the previous month. Par value for each share remained at RMB 0.2, resulting in an authorized share capital of RMB 30.87 million for H shares and RMB 34.33 million for domestic shares, cumulatively amounting to RMB 65.20 million.

The total number of issued H shares and domestic shares (excluding treasury shares) remained unchanged, at 154,327,250 H shares and 171,654,215 domestic shares, respectively. The announcement also confirmed compliance with the applicable public float requirement, with no movement in treasury shares during the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment